Clinical trials: Obese Non Diabetic
Type 2 Diabetes
The Effect of Vitamin D Supplementation on Glucose Metabolism in Non-Diabetic African American Adults
Type 2 diabetes is more common among African Americans than Caucasians. African Americans are also at a higher risk for lower levels of vitamin D compared to other ethnic groups.
- Trial name
- AVIS (NCT01141192)
- Testing
- vitamin D3, cholecalciferol, Inactive comparator
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Augusta University
Non-diabetic Overweight or Obese
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC)…
- Trial name
- NCT06714955
- Testing
- Experimental: 10 mg BGM0504 10 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week., Experimental: 15 mg BGM0504 15 mg BGM0504 administered SC once a week.
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Bariatric Surgery, Obese
Comparative Evaluation of the Evolution of Arterial and Microcirculatory Endothelial Function in Obese Patients With Type-2 Diabetes Versus Non-diabetic Obese Patients After a First Bariatric Surgery
The weight reduction obtained after a first bariatric surgery would improve the vascular (correction of endothelial dysfunction, improvement of arterial wall compliance and evolution of the atherothrombotic process) and…
- Conditions
- Bariatric Surgery, Obese, Type2 Diabetes
- Trial name
- BariVaDia (NCT03636243)
- Testing
- Vascularly biological assessment, Analysis of vasomotor endothelial function, Analysis of arterial compliance
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Non-diabetic Overweight or Obese
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following…
- Trial name
- NCT07166081
- Testing
- BGM0504
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Overweight or Obesity
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled, parallel phase 3 study to evaluate efficacy, safety, pharmacokinetics characteristics and immunogenicity of TG103 injection, a GLP-1 receptor agonist, for…
- Trial name
- NCT05997576
- Testing
- TG103 22.5 mg
- Where
- China
- Volunteers
- 675 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Neuropathology
Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients
Background / rational: Obesity is associated with significant comorbidities including type 2 diabetes (insulin resistance), heart disease, stroke, hypertension, sleep apnea syndrome, dyslipidemia, cancer, hepatobiliary diseases…
- Trial name
- NEUROBISITE (NCT02767583)
- Testing
- Exams
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Gout
Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients
Gout is a systemic disease that results from the deposition of monosodium urate crystals (MSU) in tissues. Increased serum uric acid (SUA) above a specific threshold (>6.8 mg/dl) is a requirement for the formation of uric acid…
- Trial name
- NCT06995339
- Testing
- Febuxostat Tablets, Metformin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mostafa Bahaa
Weight Loss, Metabolic Syndrome
Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence…
- Conditions
- Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity
- Trial name
- NCT05121844
- Testing
- Continuous Glucose Monitor Device
- Where
- United States
- Volunteers
- 31,187 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Sarcopenia, Obesity
Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity
The goal of this observational study is to compare glycemic control and irisin levels in subjects with diabetes mellitus type 2 with sarcopenic obesity vs non-sarcopenic obesity.
- Conditions
- Sarcopenia, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT05908812
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Obesity, Metabolic Disease
Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome
Background: Being overweight may cause low-level inflammation. This inflammation may cause some of the medical problems of obesity, like high blood sugar (diabetes) and heart disease.
- Trial name
- NCT02153983
- Testing
- Colchicine 0.6Mg Cap, Colchicine 0.6Mg Tab
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Obesity
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic…
- Trial name
- NCT03486392
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 51 sites in United States, Belgium and 4 more
- Volunteers
- 474 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus
24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
The purpose of this study is to evaluate benefits and risks of lixisenatide (AVE0010), in comparison to sitagliptin, as an add-on treatment to metformin, in obese (body mass index [BMI] greater than or equal to 30 kilogram per…
- Trial name
- NCT00976937
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sitagliptin
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 319 people
- Sponsor
- Sanofi
Obesity
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities
We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned.
- Trial name
- NCT04525300
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiangya Hospital of Central South University
Negative Pressure Therapy, Wound
Nutritional Regulation of Wound Inflammation: Part III
The purpose of this study is to examine the changes that result in the wound healing of a type II Diabetic using Negative Pressure Therapy after 12 weeks of daily supplementation of ImmunAge (Fermented Papaya Preparation (FPP).
- Conditions
- Negative Pressure Therapy, Wound, Open Wound, Type II Obese Diabetic
- Trial name
- FPP3 (NCT02332993)
- Testing
- FPP
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Ohio State University
Obesity
Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight
Obesity is a medical condition which increases the risk of other diseases, such as type 2 diabetes and cardiovascular disease. Obesity-related risk factors for the development of other metabolic diseases include unstable glucose…
- Trial name
- Dapalost (NCT02313220)
- Testing
- Dapagliflozin, Exenatide
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Uppsala University
Obese Non Diabetic
The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino Acids
The aim of this study is to reduce fasting circulating BCAA concentrations in volunteers using Sodium Phenylbutyrate. In addition, we aim investigate the effect of BCAA lowering on fasting blood glucose levels, insulin…
- Trial name
- NCT05028803
- Testing
- sodium phenylbutyrate
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Diabetes Mellitus, Type 2
Surgical Treatment of Non-obese Type 2 Diabetic Patients With Duodenal Exclusion
Diabetes reversion is observed after bariatric surgeries even before significant weight loss could explain it, mainly in predominantly malabsorptive procedures (98,9% for biliopancreatic diversion or duodenal switch), followed by…
- Trial name
- NCT00566358
- Testing
- Duodenal exclusion surgery
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- University of Campinas, Brazil
Overweight , Obesity
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants…
- Trial name
- NCT07791524
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.
- Trial name
- NCT00500370
- Testing
- exenatide
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- AstraZeneca
Non-Alcoholic Fatty Liver Disease
The Effect of GLP-1 Analogues on Liver Steatosis and Fibrosis in Diabetic and Obese Patients in a Clinical Setting
This study aims to measure the effect of GLP-1 analogues on non-alcoholic fatty liver disease in patients with diabetes and/or obesity in a clinical context.
- Trial name
- GLP1_NAFLD (NCT07021443)
- Testing
- non-interventional
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitair Ziekenhuis Brussel